CD272/BTLA
Alpha Lifetech can provide CD272/BTLA corresponding products, help each customer's research and development.
01
Introduction To CD272/BTLA
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein, which is related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to CD272/BTLA protein is a common target in medicine.
BTLA (B/T lymphocyte attenuation factor), a member of the CD28 receptor family, is an important coinhibitory receptor that suppresses activation signal transduction. Its protein structure and function are similar to PD-1 and CTLA-4, including a single extracellular IgV-like domain, transmembrane region, and cytosolic regions, with extracellular immunoglobulin domain, immunoreceptor tyrosine repression motif (ITIM), and immunoreceptor tyrosine-based switch motif (ITSM). Expression on B cells, macrophages, dendritic cells, and NK cells. BTLA is involved in many physiopathological processes, such as tumors, inflammatory diseases, autoimmune diseases, infectious diseases, and transplant rejection.
Function of Target CD272/BTLA
BTLA is one of the important signaling molecules in immune regulation, and after binding to its ligand HVEM, it produces inhibitory signals and suppresses the activation of T cells, preventing damage to itself by the immune system. In the tumor environment, tumor cells use the BTLA / HVEM signaling pathway to suppress anti-tumor immunity by up-regulating HVEM expression, and therefore, BTLA-HVEM plays a role in promoting tumor immune escape in tumors. HVEM binding to BTLA produces immunosuppressive effects and negatively regulates the activation and proliferation of lymphocytes.
Gene Pathway of Target CD272/BTLA
BTLA is a co-inhibitory receptor that suppresses T cell proliferation and cytokine production through ITIM phosphorylation and SH2 domain-containing phosphatase 1 (SHP-1) / SHP-2 binding. The BTLA ligand HVEM can also bind to other molecules such as LIGHT or lymphotoxin- α (LT α), which triggers a co-stimulatory signal or binds to another CD160 coinhibitory receptor at different binding sites. Tumor antigen-specific CD8 + T cells express BTLA and PD-1 and function, possibly promoting the immune escape of HVEM-positive tumors. The presence of HVEM / BTLA cis complexes on the same cell blocks trans-interactions with other HVEM ligands expressed on T cells, and the functional outcome of the response to T cells is now unknown.
Fig 1: BTLA Gene Pathway. (Reference source: Ning Z, Liu K, Xiong H. Roles of BTLA in Immunity and Immune Disorders. Front Immunol. 2021 Mar 29;12:654960.)
Alpha Lifetech Can Provide
At present, various drugs targeting CD272/BTLA are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made.CD272/BTLA protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, CD272/BTLA protein products are also essential. Alpha Lifetech can provide CD272/BTLA corresponding products and help each customer's research and development. In addition, Alpha Lifetech can provide recombinant proteins and Biosimilar antibody products. The effectiveness of the products has been verified through spot products, and we also provide corresponding customized services to help our client companies efficiently and accurately screen corresponding targets through efficient and accurate EC50/IC50. At the same time, Alpha Lifetech also provides services such as recombinant antibody production, recombinant protein production, antibody and protein purification, and affinity verification to ensure the maturity of recombinant antibody affinity and assist customers in antibody drug discovery and subsequent experiments.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64677 | 50ug,100ug,500ug | |
| ALP64654 | 50ug,100ug,500ug | |
| ALP64522 | 50ug,100ug,500ug | |
Reference
[1] Ning Z, Liu K, Xiong H. Roles of BTLA in Immunity and Immune Disorders. Front Immunol. 2021 Mar 29;12:654960.
[2] Andrzejczak A, Karabon L. BTLA biology in cancer: from bench discoveries to clinical potentials. Biomark Res. 2024 Jan 17;12(1):8.
[3] Demerlé C, Gorvel L, Olive D. BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer. Front Oncol. 2021 Aug 31;11:682007.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102